Author(s):
Nirenjen. S, Praveen. D, Ranadheer Chowdary. P, Vijey Aanandhi. M
Email(s):
hodpchemistry@velsuniv.ac.in
DOI:
10.5958/0974-360X.2020.00707.6 
Address:
Nirenjen. S1, Praveen. D2, Ranadheer Chowdary. P2, Vijey Aanandhi. M3*
1Department of Pharmacy Practice, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies (VISTAS), Chennai, India.
2Research Scholar, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies (VISTAS), Chennai, India.
3Department of Pharmaceutical Chemistry and Analysis, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies (VISTAS), Chennai, India.
*Corresponding Author
Published In:
Volume - 13,
Issue - 8,
Year - 2020
ABSTRACT:
The genetic which alters the PRSS-1 (protease serine-1) gene results in chronic pancreatitis, which further causes pancreatic cancer. The equilibrium of the protease and anti-protease is altered by the RI22H (A sub-mutation of PRSS-1) which promote the onset of pancreatic cancer. Gene conversion is the major phenomenon which create the nucleotide changes that affect the axon part of thePRSS-1 gene. Genetic factors, Alcoholism, smoking, lack of the anti-oxidants were some of the factors, which causes the PRSS-1 gene mutations.
Cite this article:
Nirenjen. S, Praveen. D, Ranadheer Chowdary. P, Vijey Aanandhi. M. PRSS-1 Gene Mutations in Etiopathogenesis of Pancreatic Cancer. Research J. Pharm. and Tech. 2020; 13(8):3999-4001. doi: 10.5958/0974-360X.2020.00707.6
Cite(Electronic):
Nirenjen. S, Praveen. D, Ranadheer Chowdary. P, Vijey Aanandhi. M. PRSS-1 Gene Mutations in Etiopathogenesis of Pancreatic Cancer. Research J. Pharm. and Tech. 2020; 13(8):3999-4001. doi: 10.5958/0974-360X.2020.00707.6 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2020-13-8-80
REFERENCES:
1. Niels Teich, Jonas Rosendahl, Miklós Tóth, Joachim Mössner, and Miklós Sahin-Tóth “Mutations of Human Cationic Trypsinogen (PRSS1) and Chronic Pancreatitis”, Human Mutation (2006) 27 - 08
2. Fazlul H. Sarkar, Sanjeev Banerjee, and Yiwei Li “Pancreatic Cancer: Pathogenesis, Prevention and Treatment” Journal of Toxicology and Applied Pharmacology (2007)224 (03), 326 - 36
3. Chandak GR, Idris MM, Reddy DN, Mani KR, Bhaskar S, Rao GV, Singh L “Absence of PRSS1 mutations and association of SPINK1 trypsin inhibitor mutations in hereditary and non-hereditary chronic pancreatitis.” Gut (2004) 53(05) 723 -8
4. Howes N , Greenhalf W, Stocken DD, Neoptolemos JP “Cationic trypsinogen mutations and pancreatitis.” Clinics in Laboratory Medicine (2005)25 (01) 39 - 59
5. Zeng K1, Liu QC, Lin JH, Lin XH, Zhuang ZH, Gao F, Ou QS. “Novel mutations of PRSS1 gene in patients with pancreatic cancer among Han population.” Chinese Medical Journal (2008) 121
6. Abita JP, Delaage M, Lazdunski M. “The mechanism of activation of trypsinogen. The role of the four N-terminal aspartyl residues”. European Journal of Biochemistry.(1969); 8 314–24.
7. Amann ST, Gates LK, Aston CE, Pandya A, Whitcomb DC.” Expression and penetrance of the hereditary pancreatitis phenotype in monozygotic twins”. Gut. (2001); vol 48: 542–7.
8. Arduino C, Salacone P, Pasini B, Brusco A, Salmin P, Bacillo E, Robecchi A, Cestino L, Cirillo S, Regge D, Cappello N, Gaia E. “Association of a new cationic trypsinogen gene mutation (V39A) with chronic pancreatitis in an Italian family”. Gut. (2005)54: 1663–4.
9. Beranek H, Teich N, Witt H, Schulz HU, Mössner J, Keim V.” Analysis of tumor necrosis factor alpha and interleukin 10 promotor variants in patients with chronic pancreatitis.” European Journal of Gastroenterology and Hepatology. (2003); 15: 1223–7.
10. Bernardino AL, Guarita DR, Mott CB, Pedroso MR, Machado MC, Laudanna AA, Tani CM, Almeida FL, Zatz M. “CFTR, PRSS1 and SPINK1 mutations in the development of pancreatitis in Brazilian patients”. Journal of Oncology Practice. (2003) ; 4: 169–177.
11. Bishop MA, Steiner JM, Moore LE, Williams DA.” Evaluation of the cationic trypsinogen gene for potential mutations in miniature schnauzers with pancreatitis.” Canadian Journal of Veterinary Research. ( 2004) 68 :315–318
12. Whitcomb DC, Gorry MC, Preston RA, Furey W, Sossenheimer MJ, Ulrich CD, Martin SP, Gates LK Jr, Amann ST, Toskes PP, Liddle R, McGrath K, Uomo G, Post JC, Ehrlich GD Nat Genet. 1996 Oct; 14(2):141-5.
13. Chen JM, Raguénes O, Férec C, Deprez PH, Verellen-Dumoulin C, Andriulli A.” The A16V signal peptide cleavage site mutation in the cationic trypsinogen gene and chronic pancreatitis”. Gastroenterology. (1999117 1508–9.
14. Chen JM, Férec C.” Wanted: a consensus nomenclature for cationic trypsinogen mutations”. Gastroenterology. (2000) 119: 277.
15. Chen JM, Férec C. “Molecular basis of hereditary pancreatitis”. European Journal of Human Genetics. ( 2000)8: 437–9.
16. Chen JM, Férec C. “Gene conversion-like missense mutations in the human cationic trypsinogen gene and insights into the molecular evolution of the human trypsinogen family”. Molecular Genetics and Metabolism .( 2000) 71 :463–9.
17. Chen JM, Raguénes O, Férec C, Deprez PH, Verellen-Dumoulin C. “A CGC>CAT gene conversion-like event resulting in the R122H mutation in the cationic trypsinogen gene and its implication in the genotyping of pancreatitis”. Journal of Medical Genetics (2000) 37 :36.
18. Chen JM, Piepoli Bis A, Le Bodic L, Ruszniewski P, Robaszkiewicz M, Deprez PH, Raguénes O, Quéré I, Andriulli A, Férec C. “ Mutational screening of the cationic trypsinogen gene in a large cohort of subjects with idiopathic chronic pancreatitis.” Clinical Genetics. (2001) 59: 189–93.
19. Chen JM, Kukor Z, Le Maréchal C, Tóth M, Tsakiris L, Raguénes O, Férec C, Sahin-Tóth “M. Evolution of trypsinogen activation peptides”. Molecular Bioogy andl Evolution .( 2003) 20: 1767–77.
20. Chen JM, Le MaréchalC, Lucas D, Raguénes O, Férec C. “Loss of function” mutations in the cationic trypsinogen gene (PRSS1) may act as a protective factor against pancreatitis”. Molecular Genetics and Metabolism. (2003) 79: 67–70.
21. Comfort MW, Steinberg AG. “Pedigree of a family with hereditary chronic relapsing pancreatitis” Gastroenterology. (1952) 21: 54–63.
22. Creighton J, Lyall R, Wilson DI, Curtis A, Charnley R. “Mutations of the cationic trypsinogen gene in patients with chronic pancreatitis.” Lancet. (1999) 354 :42–3.
23. Delaage M, Desnuelle P, Lazdunski M, Bricas E, Savrda J.” On the activation of trypsinogen. A study of peptide models related to the N-terminal sequence of the zymogen”. Biochemistry and Biophysics Research Communication. (1967)29: 235–40.
24. Felderbauer P, Schnekenburger J, Lebert R, Bulut K, Werner I, Schmitz F, Domschke W, Schmidt WE. “The detection of a novel PRSS1 mutation (A121T) indicates a different yet unreported phenotype in hereditary pancreatitis.” Pancreas. (2005) 31: 441.
25. Férec C, Raguénes O, Salomon R, Roche C, Bernard JP, Guillot M, Quéré I, Faure C, Mercier B, Audrézet MP, Guillausseau PJ, Dupont C, Munnich A, Bignon JD, Le BodicL. “Mutations in the cationic trypsinogen gene and evidence for genetic heterogeneity in hereditary pancreatitis”. Journal of Medical Genetics. (1999) 36 :228–32.
26. Flajnik MF. “Comparative analyses of immunoglobulin genes: surprises and portents”. National Rev Immunol. (2002) 2: 688–98.
27. Gaboriaud C, Serre L, Guy-Crotte O, Forest E, Fontecilla-Camps JC.” Crystal structure of human trypsin 1: unexpected phosphorylation of Tyr151”. Journal of Molecular Biology (1996) 259 : 995–1010.
28. Gaiser S, Ahler A, Gundling F, Kuse ML, Savkovic V, Selig L, Teich N, Tomasini R, Dagorn JC, Mössner J, Keim V, Bödeker H.’” Expression of mutated cationic trypsinogen reduces cellular viability in AR4-2J cells” Biochemistry Biophysics and Research Communication.( 2005) 334 :721–728.
29. Gorry MC, Gabbaizedeh D, Furey W, Gates LK, Jr, Preston RA, Aston CE, Zhang Y, Ulrich C, Ehrlich GD, Whitcomb DC. “Mutations in the cationic trypsinogen gene are associated with recurrent acute and chronic pancreatitis”. Gastroenterology. (1997) 113:1063–8.
30. Guy O, Lombardo D, Bartelt DC, Amic J, Figarella C.” Two human trypsinogens. Purification, molecular properties, and N-terminal sequences”. Biochemistry. 1978;17 :1669–75.
31. Halangk MW, Lerch MM, Brandt-Nedelev B, Roth W, Ruthenbuerger M, Reinheckel T, Domschke W, Lippert H, Peters C, Deussing J. “ Role of cathepsin B in intracellular trypsinogen activation and the onset of acute pancreatitis” . Journal of Clinical Investigation. (2000)106: 773–81.
32. Schubert M, Jónsson H, Chang D, Der Sarkissian C, Ermini L, Ginolhac A et al. Prehistoric genomes reveal the genetic foundation and cost of horse domestication. Proceedings of the National Academy of Sciences. 2014;111(52):E5661-9.